-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on Biogen, Lowers Price Target to $115

Benzinga·04/29/2025 14:30:40
Listen to the news
Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $135 to $115.